ABSTRACT
Managing patients with new oral anticoagulants in perioperative period is not yet well protocolized. We report a clinical case of a critical haematuria after prostate biopsies to a patient treated with RIVAROXABAN. Monitoring and treatment of the haematuria have been difficult due to the lack of biological control and antidote for this treatment.
Subject(s)
Anticoagulants/adverse effects , Hematuria/etiology , Morpholines/adverse effects , Prostate/pathology , Thiophenes/adverse effects , Biopsy/adverse effects , Critical Illness , Humans , Male , RivaroxabanABSTRACT
The biopsy of the prostate is a common medical act, which is little invasive and can easily be practiced in external care. Some cases of early rectal or urinary bleedings, which mainly stopped spontaneously, have been described in the literature. The case reported here is that of a patient whose hemorrhagic syndrome arose more than two weeks after the biopsy and required an endoscopic haemostatic treatment.